Gossamer Bio vs Spero Therapeutics
GOSS and SPRO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GOSS and SPRO compare
Gossamer Bio is the larger company, worth 1.2 times as much as Spero Therapeutics ($71.5M against $59.4M).
Gossamer Bio grew revenue faster over the last twelve months (78.0% versus −3.3% for Spero Therapeutics).
Spero Therapeutics keeps more of each dollar of sales as profit, with a net margin of 15.7% compared with −159% at Gossamer Bio.
Spero Therapeutics scores higher on the StockData Score (11 against 2 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GOSS | SPRO |
|---|---|---|
| Size and price | ||
| Market cap | $71.5M | $59.4M |
| Share price | $11.69 | $1.02 |
| Change, 1 year | −94.1% | −59.2% |
| Change, 5 years | −98.7% | −93.8% |
| Beta (5Y) | 1.59 | 1.13 |
| Employees | 161 | 25 |
| StockData Score | ||
| Total score | 2 | 11 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 3 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 25.5× |
| P/S | 0.9× (better) | 1.3× |
| P/B | – | 1.3× |
| EV/EBITDA | – | 1.4× |
| FCF yield | −218% | – |
| Fair value | – | $1.72 |
| Margin of safety | – | 40.7% |
| Growth | ||
| Revenue growth (TTM) | 78.0% (better) | −3.3% |
| Revenue growth, 5Y average | – | 48.2% |
| Profitability | ||
| Operating margin | −140% | 12.8% (better) |
| Net margin | −159% | 15.7% (better) |
| FCF margin | −199% | – |
| Return on equity | – | 19.2% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −10.3× | – |
| Current ratio | 0.60 | 6.12 (better) |
| Altman Z-score | −37.93 | −6.00 (better) |
| Piotroski F-score | 1 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 78.0% | 36.9% |
| Held by insiders | – | 24.6% |
| Insider net buying, 12 months | – | −$499K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | – | 1.8% |
Go deeper
- GOSS stock overview
- GOSS income statement
- GOSS valuation and score
- SPRO stock overview
- SPRO income statement
- SPRO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.